Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)Completed

EUS-RFA for Unresectable Pancreatic Cancer

Efficacy and Safety of Endoscopic Ultrasonography-guided Radiofrequency Ablation in Treatment of Locally Advanced, Unresectable Pancreatic Cancer

Outcome
Finished, no results posted
Phase
No phase (not a drug trial)
Status
Completed
Study type
Interventional
Start
1 March 2020
Ended
25 August 2021
Enrollment
8 participants
Sites
1
Primary outcomes
Tumor size
Sponsor type
Academic / other
Results posted
No
Last update
30 August 2021

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The clinical application of intraoperative or percutaneous radiofrequency ablation (RFA) for pancreatic ductal adenocarcinoma (PDAC) is limited due to higher mortality and incidence of adverse events. The aim of this study was to evaluate the efficacy and safety of endoscopic ultrasonography-guided RFA (EUS-RFA) for locally advanced, unresectable PDAC. Patients with unresectable PDAC who underwent EUS-RFA were included from September 2013 to June 2016. Pre- and post-procedural clinical data was retrospective collected.

Detailed description public domain (ClinicalTrials.gov)

evaluate the efficacy and safety of endoscopic ultrasonography-guided RFA (EUS-RFA) for locally advanced, unresectable PDAC.